{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T13:21:54Z","timestamp":1756992114924,"version":"3.44.0"},"reference-count":24,"publisher":"The Pediatric Pharmacy Association","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,10,1]]},"abstract":"<jats:sec><jats:title>OBJECTIVES<\/jats:title><jats:p>The Cystic Fibrosis Foundation recently deemed the use of extended-interval dosing (EID) of aminoglycosides acceptable for the treatment of cystic fibrosis (CF) pulmonary exacerbations, but current practices across United States (US) pediatric CF accredited care centers and affiliate programs are unknown. The objectives of this research are to characterize the practice trends, dosing strategies, therapeutic drug monitoring practices, and adverse drug reaction monitoring of EID of aminoglycosides in the treatment of pulmonary exacerbations across US pediatric CF programs.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>A 38-question online survey was distributed on behalf of the author by the CF Foundation to all US pediatric CF accredited care centers and affiliate programs.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>Of the 70 participating CF programs (42.2% survey response rate), 94.3% reported using EID of aminoglycosides (as once-daily or twice-daily dosing), whereas 84.3% reported using once-daily EID in their pediatric CF population. The frequency of EID use increased with patient age. Tobramycin dosed 10 mg\/kg per day every 24 hours, infused over the course of 30 minutes, in combination with an antipseudomonal beta-lactam, was the most commonly cited regimen. Monitoring of aminoglycoside serum concentrations was reported by 98.5% of programs, with a tobramycin peak of 25 to 30 mg\/L and trough of less than 1 mg\/L targeted most frequently. Nephrotoxicity was commonly monitored through serum creatinine measurements, whereas ototoxicity was monitored by audiometry in approximately one-half of programs.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>This study indicates that the use of EID of aminoglycosides across US pediatric CF accredited care centers and affiliate programs is common, particularly among adolescents, with tobramycin being the preferred agent.<\/jats:p><\/jats:sec>","DOI":"10.5863\/1551-6776-16.4.262","type":"journal-article","created":{"date-parts":[[2020,10,27]],"date-time":"2020-10-27T20:16:15Z","timestamp":1603829775000},"page":"262-269","source":"Crossref","is-referenced-by-count":7,"title":["National Survey of Extended-Interval Aminoglycoside Dosing in Pediatric Cystic Fibrosis Pulmonary Exacerbations"],"prefix":"10.5863","volume":"16","author":[{"suffix":"Jr","given":"William A","family":"Prescott","sequence":"first","affiliation":[{"name":"University at Buffalo School of Pharmacy and Pharmaceutical Sciences, Buffalo, New York, and the Department of Pediatrics, University at Buffalo School of Medicine, Buffalo, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3883","reference":[{"issue":"1","key":"2020102716111027500_i1551-6776-16-4-262-b01","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1592\/phco.30.1.95","article-title":"Extended-interval once-daily dosing of aminoglycosides in adult and pediatric patients with cystic fibrosis","volume":"30","author":"Prescott","year":"2010;","journal-title":"Pharmacotherapy"},{"issue":"7027","key":"2020102716111027500_i1551-6776-16-4-262-b02","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1136\/bmj.312.7027.338","article-title":"Single or multiple daily doses of aminoglycosides: a meta-analysis","volume":"312","author":"Barza","year":"1996;","journal-title":"BMJ"},{"issue":"1","key":"2020102716111027500_i1551-6776-16-4-262-b03","doi-asserted-by":"crossref","first-page":"e111","DOI":"10.1542\/peds.114.1.e111","article-title":"Extended-interval aminoglycoside administration for children: a meta-analysis","volume":"114","author":"Contopoulos-Ioannidis","year":"2004;","journal-title":"Pediatrics"},{"issue":"3","key":"2020102716111027500_i1551-6776-16-4-262-b04","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1086\/313692","article-title":"National survey of extended-interval aminoglycoside dosing","volume":"30","author":"Chuck","year":"2000;","journal-title":"Clin Infect Dis"},{"issue":"2","key":"2020102716111027500_i1551-6776-16-4-262-b05","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/j.1875-9114.1995.tb04354.x","article-title":"National survey of once-daily dosing of aminoglycoside antibiotics","volume":"15","author":"Schumock","year":"1995;","journal-title":"Pharmacotherapy"},{"issue":"5","key":"2020102716111027500_i1551-6776-16-4-262-b06","first-page":"385","article-title":"Prescribing patterns for extended interval aminoglycoside dosing in pediatric patients","volume":"6","author":"Condren","year":"2001;","journal-title":"J Pediatr Pharmacol Ther"},{"issue":"6","key":"2020102716111027500_i1551-6776-16-4-262-b07","doi-asserted-by":"crossref","first-page":"437","DOI":"10.2165\/00003088-199835060-00003","article-title":"Pharmacokinetic optimisation of antibacterial treatment in patients with cystic fibrosis: current practice and suggestions for future directions","volume":"35","author":"Touw","year":"1998;","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"2020102716111027500_i1551-6776-16-4-262-b08","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1046\/j.1445-5994.2001.00010.x","article-title":"Aminoglycosides in cystic fibrosis: a descriptive study of current practice in Australia","volume":"31","author":"Phillips","year":"2001;","journal-title":"Intern Med J"},{"issue":"2","key":"2020102716111027500_i1551-6776-16-4-262-b09","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1002\/ppul.10036","article-title":"Lack of concordance in the use and monitoring of intravenous aminoglycosides in UK cystic fibrosis centers","volume":"33","author":"Tan","year":"2002;","journal-title":"Pediatr Pulmonol"},{"issue":"S31","key":"2020102716111027500_i1551-6776-16-4-262-b10","first-page":"363","article-title":"The influence of the TOPIC study on the prescribing guidelines of aminoglycosides in cystic fibrosis units","volume":"43","author":"Cheong","year":"2008;","journal-title":"Pediatr Pulmonol"},{"issue":"4","key":"2020102716111027500_i1551-6776-16-4-262-b11","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/ppul.20985","article-title":"A survey of once-daily dosage tobramycin therapy in patients with cystic fibrosis","volume":"44","author":"Van Meter","year":"2009;","journal-title":"Pediatr Pulmonol"},{"issue":"9","key":"2020102716111027500_i1551-6776-16-4-262-b12","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1164\/rccm.200812-1845PP","article-title":"Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations","volume":"180","author":"Flume","year":"2009;","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"2020102716111027500_i1551-6776-16-4-262-b13","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1093\/jac\/dkl328","article-title":"Once-daily tobramycin in cystic fibrosis: better for clinical outcome than thrice-daily tobramycin but more resistance development?","volume":"58","author":"Burkhardt","year":"2006;","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"2020102716111027500_i1551-6776-16-4-262-b14","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/ppul.1060","article-title":"Efficacy of once-daily tobramycin monotherapy for acute pulmonary exacerbations of cystic fibrosis: a preliminary study","volume":"31","author":"Master","year":"2001;","journal-title":"Pediatr Pulmonol"},{"issue":"5","key":"2020102716111027500_i1551-6776-16-4-262-b15","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1093\/infdis\/147.5.918","article-title":"Once-daily vs. continuous aminoglycoside dosing: efficacy and toxicity in animal and clinical studies of gentamicin, netilmicin, and tobramycin","volume":"147","author":"Powell","year":"1983;","journal-title":"J Infect Dis"},{"issue":"June 6-9","key":"2020102716111027500_i1551-6776-16-4-262-b16","first-page":"P192","article-title":"Optimized intravenous antibiotic treatment with Ceftazidime (thrice daily vs. continuous) and tobramycin (thrice vs. once daily) in CF patients","author":"Riethmueller","year":"2001","journal-title":"Abstracts of the 24th European Cystic Fibrosis Conference"},{"issue":"9459","key":"2020102716111027500_i1551-6776-16-4-262-b17","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0140-6736(05)17906-9","article-title":"Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis--the TOPIC study: a randomised controlled trial","volume":"365","author":"Smyth","year":"2005;","journal-title":"Lancet"},{"key":"2020102716111027500_i1551-6776-16-4-262-b18","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD002009.pub3","article-title":"Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis","author":"Smyth","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"2020102716111027500_i1551-6776-16-4-262-b19","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1136\/adc.78.6.536","article-title":"Efficacy, tolerance, and pharmacokinetics of once daily tobramycin for pseudomonas exacerbations in cystic fibrosis","volume":"78","author":"Vic","year":"1998;","journal-title":"Arch Dis Child"},{"issue":"11","key":"2020102716111027500_i1551-6776-16-4-262-b20","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1007\/BF02282885","article-title":"Tolerance, pharmacokinetics and efficacy of once daily amikacin for treatment of Pseudomonas aeruginosa pulmonary exacerbations in cystic fibrosis patients","volume":"155","author":"Vic","year":"1996;","journal-title":"Eur J Pediatr"},{"issue":"2","key":"2020102716111027500_i1551-6776-16-4-262-b21","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1183\/09031936.02.00221602","article-title":"Once-daily tobramycin in the treatment of adult patients with cystic fibrosis","volume":"19","author":"Whitehead","year":"2002;","journal-title":"Eur Respir J"},{"issue":"10","key":"2020102716111027500_i1551-6776-16-4-262-b22","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/j.1440-1754.2006.00944.x","article-title":"Pharmacokinetic profile of once daily intravenous tobramycin in children with cystic fibrosis","volume":"42","author":"Massie","year":"2006;","journal-title":"J Paediatr Child Health"},{"key":"2020102716111027500_i1551-6776-16-4-262-b23","unstructured":"Cystic Fibrosis Foundation. Cystic Fibrosis Foundation Patient Registry, 2008 Annual Data Report to the Center Directors. Bethesda, MD: The Cystic Fibrosis Foundation; 2009."},{"issue":"6","key":"2020102716111027500_i1551-6776-16-4-262-b24","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1086\/520991","article-title":"Back to the future: using aminoglycosides again and how to dose them optimally","volume":"45","author":"Drusano","year":"2007;","journal-title":"Clin Infect Dis"}],"container-title":["The Journal of Pediatric Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/meridian.allenpress.com\/jppt\/article-pdf\/16\/4\/262\/1785587\/1551-6776-16_4_262.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/meridian.allenpress.com\/jppt\/article-pdf\/16\/4\/262\/1785587\/1551-6776-16_4_262.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T18:30:08Z","timestamp":1738780208000},"score":1,"resource":{"primary":{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/16\/4\/article-p262.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10,1]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,10,1]]}},"URL":"https:\/\/doi.org\/10.5863\/1551-6776-16.4.262","relation":{},"ISSN":["1551-6776"],"issn-type":[{"type":"print","value":"1551-6776"}],"subject":[],"published":{"date-parts":[[2011,10,1]]}}}